文献速递血栓与止血

Inno8:口服FVIIIa模拟抗体片段治疗A型血友病的开发

Development of Inno8, an orally administered factor VIIIa-mimetic antibody fragment for treatment of hemophilia A.
PubMed 文献 · Blood · 2026-09-24

本研究开发了口服型双特异性单链抗体片段Inno8,通过桥接凝血因子IXa和X模拟活化FVIII功能。经结构引导和机器学习优化降低等电点、脂肪酸偶联延长暴露,并在含SNAC和烟酰胺制剂中于大鼠和比格犬评估口服生物利用度。Inno8体外效力较序列相同的emicizumab类似物平均高90倍,犬口服生物利用度0.215%,半衰期115小时,已进入首次人体试验。

要点

  • Inno8为口服FVIIIa模拟双特异性抗体片段,桥接FIXa和X。
  • 体外效力较emicizumab类似物平均高90倍。
  • 犬口服生物利用度0.215%,半衰期115小时,已启动I期试验。

核心结论

  • Inno8是一种强效、可口服的FVIIIa模拟物,支持其作为A型血友病潜在非侵入性预防治疗的进一步临床评估。

研究设计与样本

  • 临床前研究:Inno8由羊驼免疫产生,经结构引导和机器学习辅助工程优化,在含SNAC和烟酰胺制剂中于大鼠和比格犬评估。

主要发现

  • Inno8在体外效价较序列相同的emicizumab类似物平均高90倍。
  • 降低等电点使大鼠口服暴露提高约10倍。
  • 含SNAC和烟酰胺的片剂在比格犬中口服生物利用度为0.215%(给药后4小时空腹),半衰期为115小时。

关键数值与推荐

  • 体外效价:较序列相同的emicizumab类似物平均高90倍。
  • 大鼠口服暴露:降低等电点后提高约10倍。
  • 比格犬口服生物利用度:0.215%(给药后4小时空腹),半衰期115小时。

临床怎么用

  • Inno8目前处于临床评估阶段,首次人体给药已完成(VOYAGER1,NCT06649630)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A (HA) is caused by factor VIII (FVIII) deficiency and requires lifelong prophylaxis. Although activated FVIII (FVIIIa)-mimetic antibodies have enabled subcutaneous administration, thereby reducing treatment burden compared with intravenous FVIII replacement, an oral therapy remains a significant unmet need for individuals with HA. Here, we describe Inno8, a novel bispecific single-chain antibody fragment comprising two variable domains of heavy-chain antibodies that bridges coagulation factors IXa and X to mimic FVIIIa function and is engineered for oral delivery. Inno8 was generated from llama and alpaca immunizations and optimized through iterative structure-guided and machine learning-assisted engineering to enhance FVIIIa-mimetic activity, reduce the isoelectric point (pI) to improve oral bioavailability, and extend systemic exposure through site-specific fatty acid conjugation. Formulations containing permeation enhancer SNAC and solubilizing agent niacinamide were evaluated in preclinical models. Procoagulant activity was assessed in HA plasma and whole blood using thrombin generation assays and thromboelastography. Inno8 demonstrated, on average, 90‑fold greater in vitro potency than a sequence‑identical emicizumab analogue. Reducing the pI increased oral exposure ~10-fold in rats, and a tablet formulation containing SNAC and niacinamide demonstrated significant oral bioavailability (0.215% with 4-hour post dose fasting) and a 115-hour half-life in beagle dogs. Together, these findings support Inno8 as a potent, orally deliverable FVIIIa-mimetic and provide a framework for engineering oral, long-acting antibody-based therapies. Inno8 is currently in clinical evaluation, with first-in-human dosing completed (VOYAGER1, NCT06649630). Pending further clinical evaluation, Inno8 may represent an advance in biologics development and a potential non-invasive prophylactic therapy for individuals with HA.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lund J, Bjelke JR, Granata D, et al. Development of Inno8, an orally administered factor VIIIa-mimetic antibody fragment for treatment of hemophilia A. Blood. 2026. PMID: 42784525. doi:10.1182/blood.2026034676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。